Furthermore, the cancer-related copy number variation (CNV) of the BTRC gene has been associated with CRC prognosis in 518 Chinese patients (amplification vs. wildtype, hazards ratio = 0.42, 95% confidence interval: 0.19, 0.97, p = 0.05; amplification + deletion vs. wildtype, hazards ratio = 0.39, 95% confidence interval: 0.17, 0.88, p = 0.023) [94]. This evidence concerns the gene BTRC and cancer.